1 Min Read
Oct 13 (Reuters) - Insys Therapeutics Inc :
* Insys Therapeutics reports preliminary estimated revenues from subsys for the third quarter 2016
* Insys Therapeutics Inc - preliminary estimated revenues from Subsys (fentanyl sublingual spray) for Q3 of 2016 will be in range of $54 million to $55 million
* Insys Therapeutics Inc- company believes it will be cash-flow positive at the level of sales
* Insys Therapeutics Inc - "estimated revenues for quarter reflect a decline in prescriptions"
* Insys Therapeutics-believes scrutiny resulted in patients having difficulty getting reimbursement for transmucosal immediate release fentanyl medications Source text for Eikon: Further company coverage: